A Phase 1/2, Proof-of-Concept Clinical Trial to Evaluate exoIL-12 in Patients with Cutaneous T-Cell Lymphoma

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 17 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ExoIL 12 (Primary)
Indications Cutaneous T-cell lymphoma
Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics; Proof of concept
Sponsors Codiak BioSciences

04 Nov 2021 According to an Codiak BioSciences media release, enrollment in this trial has ramped more slowly than anticipated due predominantly to COVID-related restrictions in the UK so initial data from this trial, now anticipated in H1 2022.
05 Aug 2021 According to a Codiak BioSciences media release, Initial safety and efficacy data expected by year end.
10 Apr 2021 Results assessing safety, pharmacokinetics and pharmacodynamics of exoIL-12 in healthy volunteers, presented at the 112th Annual Meeting of the American Association for Cancer Research.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com